322 related articles for article (PubMed ID: 22553142)
1. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients.
Pea F; Viale P; Cojutti P; Del Pin B; Zamparini E; Furlanut M
J Antimicrob Chemother; 2012 Aug; 67(8):2034-42. PubMed ID: 22553142
[TBL] [Abstract][Full Text] [Related]
2. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.
Nukui Y; Hatakeyama S; Okamoto K; Yamamoto T; Hisaka A; Suzuki H; Yata N; Yotsuyanagi H; Moriya K
J Antimicrob Chemother; 2013 Sep; 68(9):2128-33. PubMed ID: 23625638
[TBL] [Abstract][Full Text] [Related]
3. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation.
Cojutti P; Maximova N; Crichiutti G; Isola M; Pea F
J Antimicrob Chemother; 2015 Jan; 70(1):198-206. PubMed ID: 25182066
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?
Legout L; Valette M; Dezeque H; Nguyen S; Lemaire X; Loïez C; Caillaux M; Beltrand E; Dubreuil L; Yazdanpanah Y; Migaud H; Senneville E
J Antimicrob Chemother; 2010 Oct; 65(10):2224-30. PubMed ID: 20675299
[TBL] [Abstract][Full Text] [Related]
6. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections.
Cattaneo D; Orlando G; Cozzi V; Cordier L; Baldelli S; Merli S; Fucile S; Gulisano C; Rizzardini G; Clementi E
Int J Antimicrob Agents; 2013 Jun; 41(6):586-9. PubMed ID: 23562639
[TBL] [Abstract][Full Text] [Related]
7. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy.
Niwa T; Suzuki A; Sakakibara S; Kasahara S; Yasuda M; Fukao A; Matsuura K; Goto C; Murakami N; Itoh Y
Clin Ther; 2009 Oct; 31(10):2126-33. PubMed ID: 19922883
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections.
Nguyen S; Pasquet A; Legout L; Beltrand E; Dubreuil L; Migaud H; Yazdanpanah Y; Senneville E
Clin Microbiol Infect; 2009 Dec; 15(12):1163-9. PubMed ID: 19438638
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study.
Senneville E; Legout L; Valette M; Yazdanpanah Y; Giraud F; Beltrand E; Obert G; Dubreuil L; Migaud H; Mouton Y
J Antimicrob Chemother; 2004 Oct; 54(4):798-802. PubMed ID: 15329363
[TBL] [Abstract][Full Text] [Related]
10. A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin.
Patel N; VanDeWall H; Tristani L; Rivera A; Woo B; Dihmess A; Li HK; Smith R; Lodise TP
J Antimicrob Chemother; 2012 Mar; 67(3):727-35. PubMed ID: 22174041
[TBL] [Abstract][Full Text] [Related]
11. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
[TBL] [Abstract][Full Text] [Related]
12. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction.
Matsumoto K; Takeshita A; Ikawa K; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
Int J Antimicrob Agents; 2010 Aug; 36(2):179-81. PubMed ID: 20392606
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis.
Tangg SJ; Zhang Q; Zheng LH; Sun H; Gu J; Hao XH; Liu YD; Yao L; Xiao HP
Jpn J Infect Dis; 2011; 64(6):509-12. PubMed ID: 22116331
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of linezolid in liver transplant patients.
Radunz S; Juntermanns B; Kaiser GM; Treckmann J; Mathe Z; Paul A; Saner FH
Transpl Infect Dis; 2011 Aug; 13(4):353-8. PubMed ID: 21355969
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients.
Dong HY; Xie J; Chen LH; Wang TT; Zhao YR; Dong YL
Eur J Clin Microbiol Infect Dis; 2014 Jun; 33(6):1029-35. PubMed ID: 24515096
[TBL] [Abstract][Full Text] [Related]
16. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections.
Hoyo I; Martínez-Pastor J; Garcia-Ramiro S; Climent C; Brunet M; Cuesta M; Mensa J; Soriano A
Scand J Infect Dis; 2012 Jul; 44(7):548-50. PubMed ID: 22385321
[TBL] [Abstract][Full Text] [Related]
17. Safety of linezolid in patients with baseline thrombocytopenia.
Grim SA; Rene L; Gupta S; Clark NM
J Antimicrob Chemother; 2008 Oct; 62(4):850-1. PubMed ID: 18596084
[No Abstract] [Full Text] [Related]
18. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries.
Lovering AM; Le Floch R; Hovsepian L; Stephanazzi J; Bret P; Birraux G; Vinsonneau C
J Antimicrob Chemother; 2009 Mar; 63(3):553-9. PubMed ID: 19153078
[TBL] [Abstract][Full Text] [Related]
19. Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokinetics.
Viaggi B; Paolo AD; Danesi R; Polillo M; Ciofi L; Del Tacca M; Malacarne P
Scand J Infect Dis; 2011 Sep; 43(9):721-7. PubMed ID: 21585240
[TBL] [Abstract][Full Text] [Related]
20. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
